Nuclear factor-κB2/p100 promotes endometrial carcinoma cell survival under hypoxia in a HIF-1α independent manner.
about
Prolyl-4-hydroxylase domain protein 2 controls NF-κB/p65 transactivation and enhances the catabolic effects of inflammatory cytokines on cells of the nucleus pulposus.HIF-1-PHD2 axis controls expression of syndecan 4 in nucleus pulposus cells.Clinicopathological characteristics of gynecological cancer associated with hypoxia-inducible factor 1α expression: a meta-analysis including 6,612 subjects.Prolyl hydroxylase 3 (PHD3) modulates catabolic effects of tumor necrosis factor-α (TNF-α) on cells of the nucleus pulposus through co-activation of nuclear factor κB (NF-κB)/p65 signaling.The biological kinship of hypoxia with CSC and EMT and their relationship with deregulated expression of miRNAs and tumor aggressiveness.Hypoxia promotes noncanonical autophagy in nucleus pulposus cells independent of MTOR and HIF1A signalingHAF drives the switch of HIF-1α to HIF-2α by activating the NF-κB pathway, leading to malignant behavior of T24 bladder cancer cells.Endometrial carcinoma: molecular alterations involved in tumor development and progression.Marine bioactives: pharmacological properties and potential applications against inflammatory diseases.Molecular pathology of endometrial carcinoma.2-phenylethynesulphonamide (PFT-μ) enhances the anticancer effect of the novel hsp90 inhibitor NVP-AUY922 in melanoma, by reducing GSH levels.Transcriptional upregulation of HIF-1α by NF-κB/p65 and its associations with β-catenin/p300 complexes in endometrial carcinoma cells.Immunohistochemical features of post-radiation vaginal recurrences of endometrioid carcinomas of the endometrium: role for proteins involved in resistance to apoptosis and hypoxia.Bioluminescence Imaging to Monitor the Effects of the Hsp90 Inhibitor NVP-AUY922 on NF-κB Pathway in Endometrial Cancer.
P2860
Q30360231-E220D057-04DD-47A4-9F53-3BB76B456B31Q30393730-526F8CB0-7723-4524-81B8-49247F7EEEBCQ35625509-C0ADD856-629C-4656-9738-A47326CFC3CEQ36407793-1491A916-DA5B-4282-9868-C87EA8AB788EQ37210542-E800659A-0F32-437A-B38A-DBF0492D38BBQ37371593-F376935A-1B80-4767-88CE-2A7ED98B3456Q37504324-9D6C7CC8-D205-4E20-9235-D3E566F2AD25Q37994980-3A1F98CC-CB9D-42B0-84AB-B40E63BDEFDFQ38018055-4A64911E-7E6E-4F51-A47E-DC3B8DBADB78Q38067440-5D0E538E-439C-4B1C-BC0D-117A35676C04Q38785352-A1D99C48-5F6A-4108-9305-48491F5E72F8Q39094933-6B5B9442-89F3-4A56-A058-DB31F695AD44Q39406462-95803EA8-8CAD-461B-8515-5F6E105F20D4Q48640596-83E0F917-380C-4EFE-9A2E-C2C34A465C43
P2860
Nuclear factor-κB2/p100 promotes endometrial carcinoma cell survival under hypoxia in a HIF-1α independent manner.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Nuclear factor-κB2/p100 promot ...... n a HIF-1α independent manner.
@en
Nuclear factor-κB2/p100 promot ...... n a HIF-1α independent manner.
@nl
type
label
Nuclear factor-κB2/p100 promot ...... n a HIF-1α independent manner.
@en
Nuclear factor-κB2/p100 promot ...... n a HIF-1α independent manner.
@nl
prefLabel
Nuclear factor-κB2/p100 promot ...... n a HIF-1α independent manner.
@en
Nuclear factor-κB2/p100 promot ...... n a HIF-1α independent manner.
@nl
P2093
P50
P1476
Nuclear factor-κB2/p100 promot ...... in a HIF-1α independent manner
@en
P2093
Andree Yeramian
David Llobet
Esther Oliva
Mónica Domingo
Nuria Bahi
Nuria Eritja
Xavier Dolcet
Xavier Matias-Guiu
P2888
P304
P356
10.1038/LABINVEST.2011.58
P577
2011-05-02T00:00:00Z